Navigation Links
Researchers develop synthetic compound that may lead to drugs to fight pancreatic, lung cancer
Date:3/9/2011

DALLAS March 10, 2011 Researchers at UT Southwestern Medical Center have identified a chemical compound that may eventually lead to a drug that fights cancers that are dependent on a particular anti-viral enzyme for growth.

The researchers are testing the compound's effectiveness at fighting tumors in mice. If it is successful, they will then work to develop a drug based on the compound to combat pancreatic and non-small cell lung cancer, two cancer types in which this particular enzyme, TBK-1, often is required for cancer cell survival.

"Our prediction is that TBK-1 is a good pharmacological intervention target for a subset of lung and pancreas cancers that are addicted to the activity of this enzyme. We believe there is a large population of cancer patients that could respond to inhibition of this activity," said Dr. Michael White, professor of cell biology and senior author of the study in the Feb. 18 issue of Molecular Cell.

The investigation, which lasted three and a half years, revealed how activation of the natural virus-fighting protein TBK-1 is hijacked in cancer cells to support growth and survival.

More than 250,000 compounds were screened to find one that would inhibit the enzyme's cancer-protection mechanism. The most effective, a compound called 6-aminopyrazolopyrimidine developed in collaboration with pharmaceutical company Amgen, blocked TBK-1's effects in 40 percent to 50 percent of the non-small cell lung cancer and pancreatic cancer tissue cultures tested, reducing cancer growth. TBK-1 is activated by the Ras family of oncogenes, which are mutated in 40 percent of lung cancers and 90 percent of pancreatic cancers.

"We found a biological activity that some cancer cells need to be able to survive, and we found a way to turn it off," said Dr. White.

The next step, he said, would be ascertaining in rodents whether 6-aminopyrazolopyrimidine can permeate tumors, "hit the target and be effective." If the compound continues to demonstrate efficacy, researchers would begin work to develop a drug with the compound's properties for further testing.

The compound appears to migrate into all tissues of studied mice, but the UT Southwestern researchers don't know yet if it will penetrate solid tumors in the animal, "which is an incredibly important step in evaluating chemicals as drug leads," Dr. White said.

"We've illuminated the dark matter of regulation of an incredibly important oncogenic survival pathway. We've found a new regulatory arm of this pathway, and we've discovered you can inhibit it pharmacologically. That's target validation. The next step is to translate that target validation into development of a medicine," he said.


'/>"/>

Contact: Debbie Bolles
debbie.bolles@utsouthwestern.edu
214-648-3404
UT Southwestern Medical Center
Source:Eurekalert

Related medicine news :

1. Report: International collaboration between researchers results in greater recognition
2. U of M researchers using salmonella to fight cancer
3. University of South Florida researchers find blood-brain barrier damaged by disease
4. Boston researchers create SMArt platform architecture, launch $5,000 health app competition
5. UCLA researchers use nano-Velcro technology to improve capture of circulating cancer cells
6. Aging in place preserves seniors independence, reduces care costs, MU researchers find
7. Elderly see pedestrians half as often as younger drivers, according to Ben-Gurion U. researchers
8. Researchers use human cues to improve computer user-friendliness
9. Researchers find new mechanism behind the formation and maintenance of long-term memories
10. Researchers pinpoint genetic pathways involved in breast cancer
11. Penn researchers find new role for cancer protein p53
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2017)... ... May 21, 2017 , ... For ... a cross-disciplinary group of scholars, policymakers, and activists wanting to address equity issues ... is the third book from a recent series of from this conference. ...
(Date:5/19/2017)... ... May 19, 2017 , ... In a continuous effort to ... a luxury online mattress company that specializes in natural and organic latex mattresses, has ... autism organization) for every unique share their recent viral Facebook video receives, ...
(Date:5/19/2017)... ... 2017 , ... The Hill Agencies, a family managed firm that offers insurance ... Valley, is announcing a joint charity initiative with the Boys and Girls Club of ... event. , The Boys and Girls Club of Kern County gives young people in ...
(Date:5/19/2017)... ... 18, 2017 , ... ML Billing, 2016 Billing Company of the Year ... in large group practices, is pleased to announce their 30th anniversary. Not only has ... standard in all aspects of full-service medical billing. This has allowed ML Billing to ...
(Date:5/18/2017)... Angeles, CA (PRWEB) , ... May 18, 2017 , ... ... is now called the HighQ Learning Tab. Due to the rapid expansion of their ... clearly identifying each type of product. Now, the HighQ brand will be any ...
Breaking Medicine News(10 mins):
(Date:5/2/2017)...  George Clinical, a leading full-service CRO in the ... Oncology, a Memphis -based leader ... that George Clinical has acquired Vector Oncology,s Pharma Services (CRO) ... purpose of strengthening the ability of George Clinical ... throughout the Asia-Pacific , the ...
(Date:5/2/2017)... , May 2, 2017  Bayer and Project Apis ... from Healthy Hives 2020, a $1 million research effort to ... by the end of 2020. The grant ... Rueppell , University of North Carolina at Greensboro, who will ... bees; Dr. Edmund Stark , Michigan ...
(Date:4/28/2017)... 28, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... for its fiscal second quarter ended March 31, ... The company,s results and updated guidance reflect the ... which was completed on February 14, 2017.  ... earnings of $0.51 per diluted share compared to ...
Breaking Medicine Technology: